biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS
Krystal Biotech Netherlands
Krystal Biotech Netherlands B.V.
Krystal Biotech Netherlands clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
- Founded
- 2016
- Employees
- 306
- Programs
- 14
- Drugs
- 7
- Patents
- 14
Krystal Biotech Netherlands projects
7 ClinicalTrials.gov programs sponsored by Krystal Biotech Netherlands.
Krystal Biotech Netherlands has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
KB105
Krystal Biotech Netherlands B.V.
Autosomal Recessive Ichthyosis
1 trial -
KB105
Krystal Biotech Netherlands B.V.
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
1 trial -
KB304
Krystal Biotech Netherlands B.V.
Wrinkles in Decolletage
1 trial -
KB707
Krystal Biotech Netherlands B.V.
Cancer
1 trial -
KB707
Krystal Biotech Netherlands B.V.
Lung Cancer, Non-small Cell
1 trial -
KB801
Krystal Biotech Netherlands B.V.
Neurotrophic Keratitis
1 trial -
Mebendazole
Krystal Biotech Netherlands B.V.
Pilomyxoid Astrocytoma
1 trial
Frequently asked questions
How many clinical projects does Krystal Biotech Netherlands have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.